384 related articles for article (PubMed ID: 9792158)
21. A comparison between three commercial kits for chromogranin A measurements.
Stridsberg M; Eriksson B; Oberg K; Janson ET
J Endocrinol; 2003 May; 177(2):337-41. PubMed ID: 12740022
[TBL] [Abstract][Full Text] [Related]
22. Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes.
De Block CE; Colpin G; Thielemans K; Coopmans W; Bogers JJ; Pelckmans PA; Van Marck EA; Van Hoof V; Martin M; De Leeuw IH; Bouillon R; Van Gaal LF
Diabetes Care; 2004 Jun; 27(6):1387-93. PubMed ID: 15161793
[TBL] [Abstract][Full Text] [Related]
23. Pretreatment Levels of Chromogranin A and Neuron-specific Enolase in Patients With Gastroenteropancreatic Neuroendocrine Neoplasia.
Kečkéš Š; Palaj J; Waczulíková I; Dyttert D; Mojtová E; Kováč G; Durdík Š
In Vivo; 2021; 35(5):2863-2868. PubMed ID: 34410979
[TBL] [Abstract][Full Text] [Related]
24. [Usefulness of chromogranin A determination in the diagnosis of neuroendocrine neoplasia].
Militello C; Cannizzaro R; Pradella P; Volpin E; Spirch S; Buonadonna A; De Appollonia L; Rossi C; Sigon R; Cipresso S; Terranova O
Chir Ital; 1999; 51(1):45-51. PubMed ID: 10514916
[TBL] [Abstract][Full Text] [Related]
25. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate.
Angelsen A; Syversen U; Stridsberg M; Haugen OA; Mjølnerød OK; Waldum HL
Prostate; 1997 May; 31(2):110-7. PubMed ID: 9140124
[TBL] [Abstract][Full Text] [Related]
26. [Chromogranin A and neuroendocrine tumors].
Díaz Pérez JÁ; Currás Freixes M
Endocrinol Nutr; 2013; 60(7):386-95. PubMed ID: 23271036
[TBL] [Abstract][Full Text] [Related]
27. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
28. Re: Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase.
Dittadi R; Gion M
Clin Biochem; 2013 Aug; 46(12):1145. PubMed ID: 23608355
[No Abstract] [Full Text] [Related]
29. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.
Kasprzak A; Zabel M; Biczysko W
Pol J Pathol; 2007; 58(1):23-33. PubMed ID: 17585539
[TBL] [Abstract][Full Text] [Related]
30. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours.
Nehar D; Lombard-Bohas C; Olivieri S; Claustrat B; Chayvialle JA; Penes MC; Sassolas G; Borson-Chazot F
Clin Endocrinol (Oxf); 2004 May; 60(5):644-52. PubMed ID: 15104570
[TBL] [Abstract][Full Text] [Related]
31. Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase.
Braga F; Ferraro S; Mozzi R; Dolci A; Panteghini M
Clin Biochem; 2013 Jan; 46(1-2):148-51. PubMed ID: 23000312
[TBL] [Abstract][Full Text] [Related]
32. Neuroendocrine differentiation in renal cell carcinoma--evaluation of chromogranin A and neuron-specific enolase.
Rasmuson T; Grankvist K; Roos G; Ljungberg B
Acta Oncol; 1999; 38(5):623-8. PubMed ID: 10427952
[TBL] [Abstract][Full Text] [Related]
33. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma.
Stridsberg M; Husebye ES
Eur J Endocrinol; 1997 Jan; 136(1):67-73. PubMed ID: 9037129
[TBL] [Abstract][Full Text] [Related]
34. Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients.
Wu JT; Astill ME; Liu GH; Stephenson RA
J Clin Lab Anal; 1998; 12(1):20-5. PubMed ID: 9484665
[TBL] [Abstract][Full Text] [Related]
35. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.
Lamy PJ; Grenier J; Kramar A; Pujol JL
Lung Cancer; 2000 Sep; 29(3):197-203. PubMed ID: 10996422
[TBL] [Abstract][Full Text] [Related]
36. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer.
Pujol JL; Quantin X; Jacot W; Boher JM; Grenier J; Lamy PJ
Lung Cancer; 2003 Feb; 39(2):131-8. PubMed ID: 12581564
[TBL] [Abstract][Full Text] [Related]
37. Plasma levels of chromogranin A are directly proportional to tumour burden in neuroblastoma.
Wassberg E; Stridsberg M; Christofferson R
J Endocrinol; 1996 Nov; 151(2):225-30. PubMed ID: 8958782
[TBL] [Abstract][Full Text] [Related]
38. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract][Full Text] [Related]
39. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience.
Stivanello M; Berruti A; Torta M; Termine A; Tampellini M; Gorzegno G; Angeli A; Dogliotti L
Ann Oncol; 2001; 12 Suppl 2():S73-7. PubMed ID: 11762356
[TBL] [Abstract][Full Text] [Related]
40. [Advances of circulating biomarkers in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Mar; 20(3):357-360. PubMed ID: 28338171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]